Following on from information provided to NICE by the company in October 2019, the appraisal of Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 1331 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
10 November 2022 | Discontinued. Following on from information provided to NICE by the company in October 2019, the appraisal of Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
17 October 2019 | Suspended. Referred 05/12/2017 |
17 October 2019 | The Department for Health and Social Care has asked NICE to carry out an appraisal of durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
12 April 2019 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations. However, following on from information received from the company regarding the recent results for the Phase III MYSTIC trial, the timelines for this appraisal are to be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes. |
28 September 2018 - 26 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
05 December 2017 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual